Seres Therapeutics, Inc. (MCRB) financial statements (2020 and earlier)

Company profile

Business Address 200 SIDNEY STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:9586150230205
Cash and cash equivalents6586365574
Short-term investments30 114139131
Other undisclosed cash, cash equivalents, and short-term investments   37 
Receivables2    
Other undisclosed current assets475(32)3
Total current assets:10093155198208
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment192633368
Long-term investments and receivables   37 
Long-term investments   37 
Restricted cash and investments12212
Total noncurrent assets:322834749
TOTAL ASSETS:132120190273217
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities101516159
Accounts payable56785
Accrued liabilities13441
Employee-related liabilities55543
Deferred revenue5
Debt4    
Contract with customer, liability20
Other undisclosed current liabilities27716151
Total current liabilities:4642323011
Noncurrent Liabilities
Long-term debt and lease obligation40    
Long-term debt, excluding current maturities25    
Operating lease, liability16
Liabilities, other than long-term debt511932 
Deferred revenue and credits22 
Deferred revenue5
Contract with customer, liability117
Deferred rent credit 2
Other liabilities101  
Other undisclosed noncurrent liabilities897941071
Total noncurrent liabilities:135126971101
Total liabilities:18116912914012
Stockholders' equity
Stockholders' equity attributable to parent(48)(48)61133205
Common stock00000
Additional paid in capital411341324307288
Accumulated other comprehensive income (loss)  (0)(0)0
Accumulated deficit(460)(389)(264)(174)(83)
Total stockholders' equity:(48)(48)61133205
TOTAL LIABILITIES AND EQUITY:132120190273217

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenue, net3222 
Revenue from related parties 27
Gross profit:35283222 
Operating expenses(106)(129)(123)(115)(55)
Operating loss:(72)(100)(91)(93)(55)
Nonoperating income21210
Investment income, nonoperating1    
Other nonoperating income100  
Interest and debt expense(1)  (1)(1)
Net loss:(71)(99)(89)(93)(55)
Other undisclosed net income attributable to parent1  11
Net loss available to common stockholders, diluted:(70)(99)(89)(92)(55)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(71)(99)(89)(93)(55)
Other comprehensive income (loss)  0(0)0
Comprehensive loss:(71)(99)(89)(93)(55)
Other undisclosed comprehensive income, net of tax, attributable to parent10 11
Comprehensive loss, net of tax, attributable to parent:(70)(99)(89)(92)(55)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: